Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

HPV Infection Clinical Trial

Official title:

A Phase 1b/2, Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-Vectored Multigenotype hrHPV Vaccine in Women With Low-grade HPV-related Cervical Lesions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04607850
• Other study ID #: HPV001
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: March 16, 2021
• Est. completion date: January 16, 2024

Study information

• Verified date: January 2024
• Source: Barinthus Biotherapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.

Description:

The study consists of an open label, non-randomised, dose escalation Lead in phase. 9 participants with high-risk HPV, in cohorts of 3 in 3 dose ascending groups, will be vaccinated after SMC safety data reviews.

This is followed by a blinded, randomised Main phase with 96 participants with high-risk HPV, in parallel running dose cohorts (three different doses of ChAdOx1-HPV plus two different doses of MVA-HPV versus placebo plus placebo boost). At least 60 of these participants will take part in the immunogenicity sub-study.

A blinded, randomised expansion phase investigating the effects of up to two different main phase doses against placebo will be further defined prior to commencing this phase of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 99
• Est. completion date: January 16, 2024
• Est. primary completion date: January 16, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Females aged =25 and =55 years of age at screening.

2. Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participants in the lead-in phase are only required to have the screening result.

3. Low- grade cervical lesion (CIN1 or HPV-related change only) confirmed by histology and/or cytology report within the 1 year prior to screening.

4. Not pregnant or breast feeding and one of the following:

• Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses for at least 12 months and without an alternative medical cause)

• Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to administration of the first dose of study vaccine and throughout the study until 8 weeks after administration of the second dose. Highly effective methods of contraception include one or more of the following:

• Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant

• Hormonal (oral, intravaginal, transdermal, implantable or injectable). Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective.

• An intrauterine hormone releasing system

• An intrauterine device

• Bilateral tubal occlusion

• Sexual abstinence, only if the participant refrains from heterosexual intercourse during the entire study period and it is the usual lifestyle of the participant

5. Willing to abstain from sexual activity for 48 hours prior to all swabbing procedures

Exclusion Criteria:

1. Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness, including blood dyscrasias.

2. Immunosuppression as a result of underlying illness or treatment including:

• Use of high dose corticosteroids ( >10 mg/day prednisone or equivalent) for =7 days (inhaled, otic and ophthalmic corticosteroids are permitted)

• Primary immune deficiency disease

• Use of synthetic or biologic disease-modifying antirheumatic drugs

• History of bone marrow or solid organ transplant

• History of any other clinically significant autoimmune or immunosuppressive disease

3. Positive diagnostic tests (for human immunodeficiency virus, hepatitis B or hepatitis C) indicating chronic infection.

4. Evidence of high grade cervical lesions by colposcopy or by Papanicolaou (Pap) smear test in the 1 year prior to screening.

5. Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine, e.g. severe allergy to eggs.

6. Receipt of any investigational drug or investigational vaccine within 3 months prior to administration of ChAdOx1-HPV on Day 0, or prior participation in a clinical study of any HPV vaccine.

7. Receipt of any adenoviral based vaccine within 3 months prior to administration of ChAdOx1 HPV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months after Day 0.

8. Receipt of any live vaccines within the 30 days or inactivated vaccine within the 14 days prior to administration of ChAdOx1-HPV on Day 0 or planned to occur in the 2 months after the Day 0 vaccination.

9. Current or history of illicit drug use within the 6 months prior to screening.

10. Current or history of severe alcohol abuse within the 6 months prior to screening.

11. Any laboratory test which is abnormal and deemed by the Investigator to be clinically significant which will potentially affect the participation in the study.

12. Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2)

13. Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study.

Related Conditions & MeSH terms

• CIN1
• HPV Infection
• Papillomavirus Infections

Intervention

Biological:
• ChAdOx1-HPV
Trial vaccine
• MVA-HPV
Trial vaccine
• Placebo
Saline placebo vaccine

Locations

Country	Name	City	State
Belgium	UZA	Antwerp
Belgium	Erasme Hospital	Brussels
Belgium	UZ Brussel	Brussels
Belgium	UZ Gent	Gent
Belgium	UZ Leuven	Leuven
Estonia	Parnu Hospital Womens and Childrens Clinic	Parnu
Estonia	East-Tallinn Central Hospital	Tallinn
Estonia	North Estonia Medical Centre Foundation Surgery Clinic	Tallinn
Estonia	Tartu University Hospital Womens Clinic	Tartu
United Kingdom	Aberdeen Royal Infirmary	Aberdeen
United Kingdom	University Hospital Bristol NHS Trust	Bristol
United Kingdom	Liverpool Women's NHS Foundation Trust	Liverpool
United Kingdom	Royal Victoria Infirmary	Newcastle Upon Tyne
United Kingdom	Nottingham University Hospital NHS Trust	Nottingham
United Kingdom	The University of Oxford, Nuffield Department of Women's & Reproductive Health	Oxford
United Kingdom	Royal Preston Hospital	Preston

Sponsors (1)

Lead Sponsor	Collaborator
Barinthus Biotherapeutics

Countries where clinical trial is conducted

Belgium,  Estonia,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines	This will be assessed by measuring the individual phenotypic subsets of CD4+ and CD8+ T cells induced by vaccination	3 months for lead in phase and 12 months for main phase
Other	Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines	This will be assessed by measuring the innate immune response after vaccination compared to baseline	3 months for lead in phase and 12 months for main phase
Other	Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines	This will be assessed by measuring the T cell breadth of response to the components of the ChAdOx1-HPV plus MVA-HPV vaccines	3 months for lead in phase and 12 months for main phase
Other	Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines	Immune responses after prime and boost vaccinations in cytobrush samples compared to baseline	3 months for lead in phase and 12 months for main phase
Primary	Incidence of adverse events to measure safety and reactogenicity	Measure of adverse events, serious adverse events (SAEs), =Grade 3 study vaccine-related adverse events reported.	3 months for the lead-in and 12 months for the main phase
Secondary	Determine the dose of ChAdOx1-HPV plus MVA-HPV vaccines for further development	Measurement of the highest multi-parameter index made of CD4+ magnitude, CD4+ avidity and CD8+ magnitude at peak timepoint	3 months for lead in phase and 12 months for main phase
Secondary	Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on the clearance of high risk HPV infection	The percentage of hrHPV infection clearance	12 months for main phase only
Secondary	Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on cervical intraepithelial neoplasia (CIN)	The percentage of cervical lesions cleared as determined by colposcopy	12 months for main phase only